The last 2 decades have witnessed a dramatic expansion in our understanding of the genetics, pathophysiology, and comorbidities of psoriasis leading to the development and approval of a variety of treatment strategies targeting pathways such as JAK/STAT, PDE4, TNF, IL12/23, and IL-17. We propose creating a biobank of specimens from patients with psoriatic disease (psoriasis and/or psoriatic arthritis).We propose prospectively collecting specimens from 200 patients with psoriatic disease, 18 years of age and older, able to provide consent, seen at PENN and deeply phenotyped clinically. All prospective participants will have had to wash out for a specified time from psoriasis medications to be eligible (see protocol for specified washout time frames). Such a biobank will be critical to allowing us to deepen and expand existing collaborations between dermatology, rheumatology, immunology, and genetics to better define the genetic and immunological abnormalities in psoriatic disease and conduct studies that lead to personalized medicine approaches to diagnosis, staging, and treatment selection for this common disease that affects over 7 million Americans.

You may be eligible for this study if you meet the following criteria:

• Conditions: Psoriasis
• Age: 18 years - 99 years
• Gender: All